Specific antibodies increase antigen uptake and presentation by antigen-presenting cells via the B cell receptor in B cells or FcγR in dendritic cells. To determine whether the interaction between antibody and antigen could influence the set of peptides presented by MHC II molecules, we analyzed the presentation of different CD4 ⍣ T cell epitopes of hen egg-white lysozyme (HEL) after the capture of immune complexes formed between HEL and seven different specific mAb. The 103-117 T cell epitope (I-E d ) was specifically and selectively up-regulated by the D1.3 and F9.13.7 mAb that binds to proximal loops in the native structure of HEL. Furthermore, Ii-independent T cell epitopes exposed on the HEL surface (116-129 and 34-45, I-A k restricted) which require a mild processing involving the recycling of MHC II molecules were selectively up-regulated by mAb that overlap those T cell epitopes (D1.3 and D44.1). However, F10.6.6, somatically derived from the same germ line genes as D44.1 and exhibiting an higher affinity for HEL, was without effect on the presentation of the 34-45 epitope. An Ii-dependent T cell epitope buried into the tertiary structure of HEL (45-61, I-A k restricted) and requiring the neosynthesis of MHC II was up-regulated by highaffinity mAb recognizing epitopes located at the N-or C-terminus of the T cell epitope. These results strongly suggest that (i) the spatial relationship linking the T cell epitope and the B cell epitope recognized by the mAb, (ii) the intrinsic processing requirements of the T cell epitope, and (iii) the antibody affinity influences the presentation of a given T cell epitope.
Introduction
Antibodies participate efficiently in antigen uptake by antigenof an antigen by an antibody could favor or inhibit the presentation of T cell epitopes which are located near to or presenting cells (APC). The capture of antigen via the B cell receptor complex (1,2) or via immune complex (IC) uptake within the antigenic determinant recognized by this antibody (8) (9) (10) (11) . It has also been shown (12, 13 ) that specific Epsteinby Fc receptors (FcR) expressed by macrophages or dendritic cells (3) (4) (5) (6) results in a MHC class II-restricted antigen preBarr virus-transformed B cell lines that recognize different epitopes of tetanus toxin generate different proteolytic sentation enhancement of 10 2 -to 10 5 -fold in comparison with non-specific uptake via fluid phase pinocytosis. degradation products of this antigen. Biochemical data concerning antigen proteolysis in the presence of specific mAb It has been suggested (7) that the fine specificity of antibodies implicated in the capture of antigen could regulate also support the hypothesis that the region of the antigen close to the epitope recognized by the mAb can be protected the nature of the peptides presented by MHC class II molecules. The antibody paratope could exert a steric hindrance from proteolysis (14) . The goal of the present study was to determine if, following during antigen proteolysis and thus interfere with the formation of complexes between peptide and MHC class II molecules.
antibody-mediated antigen uptake by APC, the antigen presentation to T cells is influenced by the specificity of the Several in vitro studies have shown that specific antibodies can differentially enhance antigen presentation to specific T antibody. We chose to address this question using the hen egg-white lysozyme (HEL) antigen since its three-dimensional cells in relation with their fine specificity; indeed, the binding Table 1 . Anti-HEL mAb used in this study Name Fine specificity K a (M -1 ) Ref.
D1.3
Gln121 (a) Asp18, Asn19, Arg21, Gly22, Ser24, Leu25, Asn27, Lys116, Gly117, Thr118, Asp119, Val120, Gln121, 2.7ϫ10 8 15,16,18 Ile124, Arg125, Leu129 (b) F9. 13.7 Arg73, Gly102, Asn103 (a) His15, Tyr20, Arg21, Trp63, Arg73, Leu75, Asn77, Asn93, Lys96, Lys97, Ser100, Asp101, Gly102 (c) 3.4ϫ10 8 15,20 D11. 15 Asn19, Arg21, Gly102, Asn103 (a) Arg21, Tyr23, Asn103, Asn106, Arg112, Lys113, Lys116, Gly117, Thr118, Asp119 (d) 5.3ϫ10 8 15,17 D136.26
Asn113, Arg114 (a) ND 15 D74. 3 Val99, Asp101, Gly102, Asn103 (a) 1ϫ10 8 15 D44.1
Arg68 (a) Gln41, Arg45, Asn46, Thr47, Gly49, Tyr53, Gly67, Arg68, Pro70, Ser81, Leu84 (b) 1.3ϫ10 7 15,19 F10. 6.6 Arg68 (a) ϾϾ10 8 15
The fine specificity of the anti-HEL mAb was determined by analysis of cross-reactivity with other avian lysozymes (a), or by crystallographic studies of Fab or Fv complexes with HEL (b), Fab/guinea fowl lysozyme complexes (c) or Fab and Fv/pheasant lysozyme complexes (d).
structure and its antigenic recognition by several specific Cell lines mAb have been structurally defined (15) (16) (17) (18) (19) (20) . In addition, the Two B cell lymphomas were used as APC in this study. IIA1.6 affinity constant and the free energy of binding of these mAb
is a FcγR -variant originated from the A20 B cell have been determined by different techniques (21) .
lymphoma cell line and A6B9 is a stable transfectant of IIA1.6 To determine if antibodies regulate antigen presentation for the FcγRIIb2 (24) . A6B9 cells were co-transfected with from a qualitative point of view, we have analyzed the presenta-A α k and A β k using NT plasmids (24) containing the hygrotion to T cells of seven different monovalent HEL-anti-HEL IC mycine and zeocine resistance genes respectively and the by an FcγR-bearing APC. The formation of different MHC Srα promotor. A6B9 cells and NT plasmids were kindly given class II molecules-peptide complexes corresponding to four by C. Bonnerot (Institut Curie). The transfectant clone A6B9.k different epitopes was followed using HEL-specific T cell was tested for A α k and A β k expression by FACS analysis using hybridomas. The availability of well-characterized anti-HEL the anti-A α k 39J mAb and the anti-A β k 10.3.62 mAb, and by mAb and of T cells of different specificities allowed us to functional antigen presentation assays (see Results). investigate whether the topologic relationship between the B The T cell hybridomas L3E10 and 45G10 specific respectcell epitope, recognized by the mAb, and a T cell epitope is ively for HEL103-117 (I-E d ) and the poliovirus VP1 protein a key parameter influencing the presentation of this epitope epitope C3T:103-116 (I-E d ), were previously derived from to T cells.
BALB/c mice (22, 25) . 3B11.1 (26) and 1D6.1 (27) T cell hybridomas specific for HEL 34-45 (I-A k ) and HEL 116-129 (I-A k ) respectively were a kind gift from Luciano Adorini Methods (Milan). 3A9 T cell hybridoma specific for HEL 48-61 (I-A k ) Antigens and mAb (28) was a kind gift of Paul Allen (Washington University).
HEL was purchased from Sigma (St Louis, MO). The HEL Antigen-presentation assay peptide p108-116 (WVAWRNRCK) was purchased from Neosystem (Strasbourg, France). The MalE303-C3:BT protein T cell hybridomas (10 5 /well) were cultured in the presence of APC (10 5 /well) in a final volume of 0.2 ml for 24 h in complete was prepared by genetic insertion of the 93-116 residues of the poliovirus VP1 protein into the Escherichia coli MalE medium (RPMI 1640 medium supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine protein at position 303 (22) and was kindly provided by P. Martineau (Institut Pasteur, Paris, France). Anti-HEL B cell and 5ϫ10 -5 M 2-mercaptoethanol). For FcγR blocking experiments, APC were incubated for 30 min at 4°C with the 2.4G2 hybridomas are described in Table 1 . They all originated from BALB/c mice and are of the IgG1,κ isotype. Ascitic fluids mAb at 10 µg/ml in complete medium, then washed before the antigen presentation assay. mAb were mixed with the prepared from BALB/c mice were precipitated with ammonium sulfate, then resuspended in distilled water and extensively antigen for 1 h at 37°C, in a final volume of 0.1 ml before incubation with the cells. A final concentration of 0.17 µM dialysed against PBS. Protein concentration was determined by a colorimetric assay (BioRad, Munich, Germany). mAb (25 µg/ml) of the mAb was used in most experiments as indicated in figure legends. After 24 h, the supernatants were activity was checked in ELISA using HEL-coated microplates. Anti-MalE mAb 94.1 (IgG1,κ) and anti-Borrelia burgdorferi frozen for at least 2 h at -70°C. Then 10 4 cells/well of the CTLL cell line which proliferates specifically in response to mAb J8.3 (IgG1,κ) were kindly provided by J.C. Mazié (Institut Pasteur, Paris, France). The latter mAb was used as an IL-2 but not IL-4 were cultured with a 100 µl aliquot of supernatant in 0. automated cell harvester (Skatron, Lier, Norway). Incorporated stimulation of L3E10 was assessed by the release of IL-2. As shown in Fig. 1(A) , the HEL presentation to L3E10 was thymidine was quantitated by scintillation counting. Each experiment was performed in duplicate.
significantly enhanced after incubation with two mAb among the seven tested: D1.3 and F9.13.7. About 10-fold less antigen Cytofluorimetric assay for the detection of immune complexes was required to stimulate an optimum response of L3E10 in at the surface of APC the presence of one of these two mAb, at the dose studied (0.17 µM). Similar results were obtained with two other T HEL was conjugated to biotin (D-biotinoyl-ε-amidocaproic acid N-hydroxysuccinimide ester; Boehringer Mannheim, cell hybridomas of the same specificity (data not shown), suggesting that the effect observed was dependent on a Mannheim, Germany) according to the supplier's protocol. Then 10 6 cells were incubated for 1 h at 4°C, with anti-HEL regulation of the processing of the 103-117 HEL peptide and not related to a peculiar property of this cell line. As expected, mAb (or an isotype-matched control) at 2 µg/10 5 cells and with HEL-biotin at 10 µg/ml in 0.2 ml of PBS, BSA 5% (w/v) HEL-anti-HEL complexes did not induce IL-2 release by the A6B9 APC or by the T cell hybridoma cultured alone (data and 3 mM sodium azide. After washing with the same buffer, cells were stained with streptavidin-FITC (Sigma). After two not shown). These results were confirmed in another antigen-presentawashes, cells were resuspended in the same buffer supplemented with propidium iodide (1 µg/ml) and analyzed on a tion assay: a fixed dose of HEL (0.1 µM) was incubated with a broad range of mAb concentrations (Fig. 1B) . The HEL FACScan (Becton Dickinson, Mountain View, CA). Living cells were gated using propidium iodide (Sigma) exclusion. dose of 0.1 µM used in this experiment was too low to stimulate L3E10, but the addition of D1.3 or F9.13.7 mAb restored optimal L3E10 stimulation. Taken together, these Results results indicate that antigen recognition by mAb is necessary but not always sufficient to potentiate HEL presentation since Some anti-HEL mAb enhance HEL presentation to T cell only some anti-HEL mAb increase HEL presentation to specific hybridomas specific for the 103-117, I-E d -restricted T cell T cells. hybridoma
We first examined the ability of seven different anti-HEL mAb Specificity of the enhancement of HEL presentation by anti- (Table 1) to modulate in vitro the presentation of HEL to HEL mAb specific T cells. Various anti-HEL mAb were mixed with
To verify the specificity of the enhancing effect of the mAb different doses of HEL and then incubated with the FcγR-on HEL presentation, we tested the effect of anti-HEL mAb bearing APC, A6B9 (H-2 d ), a B cell lymphoma transfected for on the presentation of an unrelated antigen, the chimeric FcγRIIb2 (24) , and L3E10, a T cell hybridoma specific for the HEL immunodominant epitope 103-117 restricted to I-E d . The protein MalE303-C3:BT to the C3:T-specific T cell hybridoma, on the presentation of these antigens to their specific T cell hybridomas.
Anti-HEL mAb, free or complexed to HEL, do not modify the intrinsic antigen presenting ability of A6B9 APC (FcγRIIb2 ϩ ) sentation by A6B9, did not modify the efficiency of HEL presentation by IIA1.6 (FcγR -), the B lymphoma cell line transfected with FcγRIIb2 to obtain A6B9 (Fig. 3A) . Similar results were obtained with other anti-HEL mAb (data not 45G10. As shown in Fig. 2(B) , D1.3 did not modify the shown). Furthermore, the enhancing effect of mAb D1.3 on 45G10 T cell response to MalE303-C3:BT. Similar results the L3E10 response to HEL presented by A6B9 can be were obtained with other anti-HEL mAb (data not shown).
blocked by the anti-FcγRII/III mAb 2.4G2 (Fig. 3B) . Indeed, Reciprocally, 94.1, an anti-MalE mAb which strongly stimuthe response of L3E10 at 0.1 µM of HEL using A6B9 as APC lated the presentation of the MalE303-C3:BT protein to 45G10 was fully dependent on the mAb D1.3 as shown in Fig. 3(B) . T cells did not modify HEL presentation to L3E10 T cells ( Fig.  2A and B ). An isotype matched control mAb showed no effect However, preincubation of A6B9 APC with the mAb 2.4G2 at 4°C for 30 min totally abolished the L3E10 response. This D1.3-HEL or D44.1-HEL complexes at the surface of the APC. HEL was biotinylated and the bound complexes were treatment did not interfere with the L3E10 response to 10 µM of HEL in the absence of anti-HEL mAb. Taken together, these detected by streptavidin-FITC staining (Fig. 4) . Neither HELbiotin alone nor mAb D1.3 or D44.1 alone induced a signal results indicate that the suppression of the D1.3 enhancing effect by mAb 2.4G2 is due to the hindrance of the D1.3-in this assay. The addition of HEL-biotin and mAb D1.3 or D44.1 were required to detect a positive staining by FcγR interaction and to the inhibition of the subsequent uptake of HEL-mAb complexes by the APC.
streptavidin-FITC. This staining was inhibited by preincubating A6B9 with the anti-FcγRII/III mAb 2.4G2 and was not Failure of certain mAb to increase HEL presentation does not observed with IIA1.6 (FcγR -). These results confirmed the stem from deficient binding to FcγR specificity of our binding test. A similar signal was obtained after the addition of mAb D1.3 or D44.1 even though the The inability of certain mAb to enhance HEL presentation to the 103-117 T cell hybridoma could be due to an inability of former activates HEL presentation and the latter does not. Similar results were obtained with F9.13.7 and F10.6.6 mAb the complexes formed by these mAb with HEL to bind to the FcγRIIb2 receptor expressed by the A6B9 APC. To test this (data not shown). These data indicate that the lack of increase of HEL presentation in the presence of five of the seven mAb hypothesis, we analyzed by cytofluorimetry the binding of tested is not due to a less efficient binding and uptake of HEL-anti-HEL complexes by the A6B9 APC.
Synergistic enhancement of the presentation of HEL to an I-E d -restricted, 103-117-specific hybridoma by combination of non-activating and activating mAb To examine whether the effect on HEL presentation was observed for pairs of mAb which recognize non-overlapping epitopes and therefore bind together to the same molecule of HEL to form polyvalent IC (20,29,30). The polyvalent IC bind to the weak-affinity FcγRIIb2 with an increased avidity compared to the monovalent IC (31) . For other pairs of mAb presentation of the HEL peptide, we took advantage of welldescribed I-A k -restricted HEL epitopes. The 116-129 and (D1.3 and D136.26, D1.3 and D11.15) the enhancing effect of the mixture was equal to the one observed with the 34-45 HEL epitopes are generated in an Ii-independent presentation pathway, involving the recycling of MHC class activating mAb alone. Thus, a lack of synergistic effect was observed for mAb which recognize overlapping epitopes and II molecules, whereas the 48-61 epitope requires Ii and neosynthesized MHC class II (26,32-34). We stably transtherefore cannot form polyvalent IC (29,30). We conclude that the lack of enhancing effect of D11.15 and D136.26 mAb fected the A6B9 APC for the α and β chain of the I-A k molecule to obtain an I-A k -expressing line competent in FcγR-when used in monovalent IC can be overcome when these mAb are included in polyvalent IC. mediated uptake of antigen. Expression of both α and β chains was checked by flow cytometry (Fig. 6A) and by a Protective effect of mAb on the processing of Ii-independent functional test of presentation using the I-A k -restricted 3A9 T I-A k -restricted epitopes cell hybridoma (Fig. 6B) . The presentation of HEL to the 116-129-specific hybridoma To examine whether the effect of mAb on HEL presentation was dependent on the type of processing involved in the was selectively up-regulated by the D1.3 mAb, whereas its
Discussion
In the present study, we analyzed the regulation of antigen presentation by antibodies. IC formed between HEL and seven different mAb were presented to specific T cell hybridomas by the A6B9 APC, an FcγRIIb2-transfected lymphoma B cell. Two out of the seven mAb tested, D1.3 and F9.13.7, increased significantly HEL presentation to a T cell hybridoma specific for the immunodominant 103-117 epitope restricted to I-E d .
The 116-129 epitope (I-A k restricted) was also up-regulated by the mAb D1.3 with a striking efficiency (Ͼ50-fold) and by the mAb F9.13.7 with a reduced efficiency. The 34-45 epitope (I-A k -restricted) was efficiently up-regulated by the mAb D44.1, and less efficiently by the mAb D1.3 and F9.13.7. The enhancement of HEL presentation mediated by these mAb was found to be HEL-specific and was independent of an eventual bystander effect on APC. Moreover, the lack of enhancing effect observed with the IIA1.6 cell line devoid of FcγR, as well as blocking experiments, demonstrate unambiguously that enhancement of HEL presentation depends on FcγR-mediated uptake of IC. Enhancement of antigen presentation to CD4 ϩ T cells by antibodies has already been described in several studies concerning membrane Ig-mediated or FcγR-mediated uptake of antigen (35) . In addition to these previous findings, the present study shows that the modulation of HEL presentation by mAb is specific since up-regulation of HEL presentation was only observed with a limited number of mAb/T cell epitope combinations. Moreover, our results suggest that the enhancing effect of anti-HEL mAb is mediated by two independent phenomena: (i) an increase of antigen uptake and (ii) a modulation of epitope presentation. It is likely that all mAb tested participate in an efficient HEL uptake via FcγRIIb2 since we demonstrate that D1.3, D44.1, F9.13.7 and F626.1 are capable of forming IC with HEL, and to bind to FcγRIIb2 at the membrane of A6B9 cells. Furthermore, some correlate positively or negatively with their ability to enhance HEL presentation (Table 1) . For example, both F10.6.6 which has the highest affinity (K a Ͼ 10 9 M -1 ) and D44.1 which has the lowest affinity (K a ϭ 1.3ϫ10 7 M -1 ) have no effect on HEL presentation to the 34-45-specific hybridoma was selectively up-regulated by the D44.1 mAb. The F9.13.7 had a significant presentation. Thus, even if the affinity of the mAb could influence the efficiency of HEL uptake by APC and the HEL enhancing effect on both epitopes, but this effect was very inferior to the one of D1.3 on the 116-129 epitope or the release in the endocytic pathway, differences in affinity are not sufficient to explain the different behaviors observed with one of D44.1 on the 34-45 epitope. By contrast, the HEL presentation to the Ii-dependent anti-48-61 hybridoma was the anti-HEL mAb. In this context, the antibody fine specificity appears as a key factor involved in the regulation of HEL up-regulated by the D1.3, F9.13.7, D74.3, D44.1 and F10.6.6 mAb.
processing.
Crystallographic studies of Fab and Fv fragments from the high-affinity mAb (D1.3, F9.13.7 and F10.6.6). This peptide is mAb D1.3 and D44.1 complexed to HEL have shown that the not exposed to the surface of HEL and there is no evident antigen is stabilized by interactions with the antibodies, as topological relationship with the B cell epitopes recognized judged by the decreased overall mobility of the antigen by these different mAb. The presentation of this peptide atoms. NMR studies (39) have supported this conclusion and requires Ii and the neosynthesis of MHC class II molecules extended it to soluble complexes. Thus, it is reasonable to (26, 33, 34) . Moreover, its processing involves an acidic and think that the bound mAb will confer some protection against reductor compartment related to late endosome or MIIC. proteolytic attack. However, the overall protective effect will Our main finding is that the 116-129 and 34-45 A k -restricted be influenced by the location of the epitope and by the T cell epitopes are strikingly up-regulated by the overlapping molecular mobility or tendency to unfold of the unprotected mAb D1.3 and D44.1 respectively. areas. These areas will be the first ones affected by proteo-D1.3 recognizes a discontinuous epitope encompassing lysis, leading to partial unfolding of the antigen, further two HEL loops. The 116-129 T cell epitope belongs to one proteolysis and eventual release of the bound epitopes.
of these loops (Lys116, Gly117, Thr118, Asp119, Val120, Release of bound epitopes, under the conditions of the Gln121, Ile124 and Arg125). Thus, the interaction of D1.3 with intracellular processing compartments, will differ for the mAb HEL could lead to the protection of a large region of HEL depending on the nature of the interatomic contacts and of encompassing the 116-129 T cell epitope. D44.1 failed to their intrinsic stability in the lower pH media. Evidently, some increase the presentation of the HEL 116-129 T cell epitope. complexes will expose segments of HEL that are more
In these case, the mAb binds HEL in the β-pleated sheet suceptible to proteolysis and mAb could thus exert a steric moiety of HEL which is separated by the active cleft from the hindrance on the proteolysis of HEL.
116-129 T cell epitope. Thus, it can be envisaged it they will Each antibody binds different parts of the epitopes with confer less protection to the α-helical moiety where the 116-different free energies, leading to differential dissociation of 129 T cell epitope is located (19), whereas it would protect the hydrolysed segments. The antibody combining site will the 34-45 region due to its recognition of residues Gln41 be also affected by these processes, further compounding and Arg46. the difficulty of a molecular modeling of the protection and However, it is worth noting that the F10.6.6 mAb (recognizpeptide release events. However, biochemical studies have ing the same epitope as D44.1) is without effect on 34-45 shown that a part of the antigen (larger than the strict B cell epitope presentation. This may be due to its higher affinity. epitope) could be protected ('the footprint') by the mAb from In this case, the protected paratope would not be released proteolytic degradation (11, 14) . In these studies, purified by the mAb, resulting in the inhibition of MHC II loading. proteolytic enzyme or cellular fractions were used. The relev-
The 116-129 and 34-45 T cell epitopes share common ance of these results for antigen processing has been pointed features: (i) they are exposed in the surface of the molecule, out by Watts and colleagues who have demonstrated that
(ii) they do not require Ii for their presentation (26,32) and different B cell clones with different fine specificities gave (iii) they do not require neosynthesized MHC class II molecules different patterns of antigen degradation fragments (12) .
as determined by resistance of their presentation to Brefeldin Furthermore, a large fraction of antigen fragments remained A (26,33) inhibition. Furthermore, it is well established that bound to the membrane Ig even when this latter had begun the presentation of the 116-129 epitope involves recycling of to be degradated: in this case, IC are a substrate for proteolytic MHC class II molecules (33). All these features evoke a enzyme of the endocytic pathway (13) . These results are compatible with a regulatory role of the fine specificity of the processing involving early compartments of the endocytic antibodies in antigen processing, as initially speculated by pathway. In this context it was speculated that the generation Berzofsky (7) . The availability of MHC class II molecules for of these epitopes required a moderate proteolytic attack. loading of peptides located within the footprint is controversial.
Indeed, it was shown that inhibition of endosomal proteolysis These peptides could be retained by the mAb which will (by chloroquine or leupeptin inhibition) results in an increase prevent their binding to MHC class II molecules. However, this of their presentation (33). protection could increase their life time and their probability for Taken together, our results are in favour of a model in which MHC II loading. Watts et al. (10, 11) have demonstrated that overlapping antibodies regulate the presentation of solventboth suppressed and favored T cell epitopes fell within the exposed T cell epitopes by protecting them from an excessive region of antigen protected by the regulatory mAb. They proteolytic degradation. In this context, the fine specificity of speculated that a strict overlap between B and T cell epitopes the capturing antibody could play a major regulatory role: results in suppression of the presentation of the T cell epitope, depending on the antibody affinity, the outcome of the antigenwhereas the proximity of T and B cell epitopes results in antibody interaction might be positive or negative. In contrast, increased presentation of the T cell epitope. For the 103-117 solvent-buried peptide requiring a more aggressive pro-T cell epitope, activating D1.3 and F9.13.7 mAb share a cessing may be less sensitive to antibody-mediated regulation common feature: they both recognize an epitope near the because of their efficient targeting to the late endosomal 103-117 T cell epitope in the native structure of HEL as compartment. In this case, the affinity of antibody may play defined by the crystallographic structure of HEL-anti-HEL a major role since the affinity should be sufficiently high to complexes (16, 20) .
avoid dissociation before reaching late endosomes. Processing requirements of the T cell epitopes may influence the sensitivity to the regulation exerted by antibodiesfor kind the gift of T cell hybridomas. We would like to express our 17 Chitarra, V., Alzari, P. 
